P/E ratio for Inovio Pharmaceuticals (INO)
P/E ratio as of May 2024 (TTM): -17.8
According to Inovio Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -17.8308. At the end of 2022 the company had a P/E ratio of -1.32.
P/E ratio history for Inovio Pharmaceuticals from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.32 | -61.58% |
| 2021 | -3.44 | -58% |
| 2020 | -8.19 | 200.46% |
| 2019 | -2.73 | -28.41% |
| 2018 | -3.81 | -2.23% |
| 2017 | -3.90 | -43.3% |
| 2016 | -6.87 | -55.01% |
| 2015 | -15.3 | 3.15% |
| 2014 | -14.8 | 78.7% |
| 2013 | -8.29 | 140.29% |
| 2012 | -3.45 | -3.77% |
| 2011 | -3.58 | -50.14% |
| 2010 | -7.19 | 133.28% |
| 2009 | -3.08 | 77.75% |
| 2008 | -1.73 | -49.13% |
| 2007 | -3.41 | -52.36% |
| 2006 | -7.15 | 341.1% |
| 2005 | -1.62 | -73.25% |
| 2004 | -6.06 | 108.52% |
| 2003 | -2.91 | 61.5% |
| 2002 | -1.80 | -57.81% |
| 2001 | -4.27 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.7 | -160.19% | 🇺🇸 USA |
 Novartis NVS | 26.1 | -246.20% | 🇨🇭 Switzerland |
 Pfizer PFE | 14.6 | -181.95% | 🇺🇸 USA |
 Gilead Sciences GILD | 14.9 | -183.69% | 🇺🇸 USA |
 Merck MRK | 70.7 | -496.53% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 12.2 | -168.20% | 🇬🇧 UK |
 Cleveland BioLabs
CBLI | N/A | N/A | 🇺🇸 USA |
 Arrowhead Pharmaceuticals
ARWR | -13.6 | -23.56% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.